Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 1, 2007, Pages 89-94

  Scott, Gillian M ^a,b   Weinberg, Adriana ^c   Rawlinson, William D ^a,b   Chou, Sunwen ^d  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF COLORADO   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DNA; DNA POLYMERASE; DNA POLYMERASE A834P; DNA POLYMERASE N408K; FOSCARNET; GANCICLOVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; DRUG DNA INTERACTION; ENZYME STRUCTURE; GENE MUTATION; GENETIC SUSCEPTIBILITY; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; POLYMERIZATION; PRIORITY JOURNAL; SERODIAGNOSIS; STRAIN IDENTIFICATION; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DNA REPLICATION; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; FOSCARNET; GANCICLOVIR; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; MUTATION; PHENOTYPE; PHOSPHONIC ACIDS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 33846030830     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00633-06     Document Type: Article

References (47)

1. Baldanti, F., D. Michel, L. Simoncini, M. Heuschmid, A. Zimmermann, R. Minisini, P. Schaarschmidt, T. Schmid, G. Gerna, and T. Mertens. 2002. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antivir. Res. 54:59-67.
2. Bernad, A., L. Blanco, J. M. Lazaro, G. Martin, and M. Salas. 1989. A conserved 3′-5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell 59:219-228.
3. Boivin, G., C. Gilbert, A. Gaudreau, I. Greenfield, R. Sudlow, and N. A. Roberts. 2001. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 184:1598-1602.
4. Cannon, J. S., F. Hamzeh, S. Moore, J. Nicholas, and R. F. Ambinder. 1999. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J. Virol. 73:4786-4793.
5. Chou, S. 1999. Antiviral drug resistance in human cytomegalovirus. Transplant. Infect. Dis. 1:105-114.
6. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
7. Chou, S., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39.
8. Chou, S., G. Marousek, S. Guentzel, S. E. Follansbee, M. E. Poscher, J. P. Lalezari, R. C. Miner, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786-789.
9. Chou, S., G. Marousek, D. M. Parenti, S. M. Gordon, A. G. LaVoy, J. G. Ross, R. C. Miner, and W. L. Drew. 1998. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J. Infect. Dis. 178:526-530.
10. Chou, S., and C. L. Meichsner. 2000. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob. Agents Chemother. 44:183-185.
11. Chou, S., R. C. Miner, and W. L. Drew. 2000. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J. Infect. Dis. 182:1765-1768.
12. Chou, S., L. C. Van Wechel, H. M. Lichy, and G. I. Marousek. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49: 2710-2715.
13. Chou, S., R. H. Waldemer, A. E. Senters, K. S. Michels, G. W. Kemble, R. C. Miner, and W. L. Drew. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 185:162-169.
14. Cihlar, T., M. D. Fuller, and J. M. Cherrington. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:5927-5936.
15. Cihlar, T., M. D. Fuller, A. S. Mulato, and J. M. Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382-393.
16. Drew, W. L. 2000. Ganciclovir resistance: a matter of time and titre. Lancet 356:609-610.
17. Ducancelle, A., J. Gravisse, S. Alain, A. M. Fillet, F. Petit, M. J. S. L. Pors, and M. C. Mazeron. 2005. Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. J. Virol. Methods 125:145-151.
18. Eckle, T., P. Lang, L. Prix, G. Jahn, T. Klingebiel, R. Handgretinger, B. Selle, D. Niethammer, and K. Hamprecht. 2002. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant. 30:433-439.
19. Emery, V. C. 2001. Investigation of CMV disease in immunocompromised patients. J. Clin. Pathol. 54:84-88.
20. Emery, V. C., and P. D. Griffiths. 2000. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl. Acad. Sci. USA 97:8039-8044.
21. Emery, V. C., A. F. Hassan-Walker, A. K. Burroughs, and P. D. Griffiths. 2002. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J. Infect. Dis. 185:1723-1728.
22. Erice, A., C. Gil-Roda, J. L. Perez, H. H. Balfour, Jr., K. J. Sannerud, M. N. Hanson, G. Boivin, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1087-1092.
23. Gilbert, C., and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883.
24. Gruber, S. A., J. Garnick, K. Morawski, D. H. Sillix, M. S. West, D. K. Granger, J. M. El-Amm, G. J. Alangaden, P. Chandrasekar, and A. Haririan. 2005. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin. Transplant. 19:273-278.
25. Hanson, M. N., L. C. Preheim, S. Chou, C. L. Talarico, K. K. Biron, and A. Erice. 1995. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39:1204-1205.
26. Huang, L., K. K. Ishii, H. Zuccola, A. M. Gehring, C. B. Hwang, J. Hogle, and D. M. Coen. 1999. The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alpha-like DNA polymerases. Proc. Natl. Acad. Sci. USA 96:447-452.
27. Isada, C. M., B. Yen-Lieberman, N. S. Lurain, R. Schilz, D. Kohn, D. L. Longworth, A. J. Taege, S. B. Mossad, J. Maurer, S. M. Flechner, S. D. Mawhorter, W. Braun, S. M. Gordon, S. K. Schmitt, M. Goldman, J. Long, M. Haug, and R. K. Avery. 2002. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transplant. Infect. Dis. 4:189-194.
28. Jabs, D. A., B. K. Martin, M. S. Forman, J. P. Dunn, J. L. Davis, D. V. Weinberg, K. K. Biron, F. Baldanti, and H. Hu. 2001. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: the Cytomegalovirus and Viral Resistance Study Group report number 8. Am. J. Ophthalmol. 132:700-710.
29. Landry, M. L., S. Stanat, K. Biron, D. Brambilla, W. Britt, J. Jokela, S. Chou, W. L. Drew, A. Erice, B. Gilliam, N. Lurain, J. Manischewitz, R. Miner, M. Nokta, P. Reichelderfer, S. Spector, A. Weinberg, B. Yen-Lieberman, and C. Crumpacker. 2000. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 44:688-692.
30. Levi, M. E., N. Mandava, L. K. Chan, A. Weinberg, and J. L. Olson. 2006. Treatment of multi-drug resistant cytomegalovirus retinitis with systematically administered leflunomide. Transplant. Infect. Dis. 8:38-43.
31. Limaye, A. P., L. Corey, D. M. Koelle, C. L. Davis, and M. Boeckh. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649.
32. Liu, S., J. D. Knafels, J. S. Chang, G. A. Waszak, E. T. Baldwin, M. R. Deibel, D. R. Thomsen, F. L. Homa, P. A. Wells, M. C. Tory, R. G. Poorman, H. Gao, X. Qiu, and A. P. Seddon. 2006. Crystal structure of the herpes simplex 1 virus DNA polymerase. J. Biol. Chem. 281:18193-18200.
33. Liu, W., C. Shum, D. F. Martin, B. D. Kuppermann, A. J. Hall, and T. P. Margolis. 2000. Prevalence of antiviral drug resistance in untreated patients with cytomegalovirus retinitis. J. Infect. Dis. 182:1234-1238.
34. Lowance, D., H. H. Neumayer, C. M. Legendre, J. P. Squifflet, J. Kovarik, P. J. Brennan, D. Norman, R. Mendez, M. R. Keating, G. L. Coggon, A. Crisp, I. C. Lee, et al. 1999. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N. Engl. J. Med. 340:1462-1470.
35. Lurain, N. S., A. Weinberg, C. S. Crumpacker, S. Chou, and the Adult AIDS Clinical Trials Group-CMV Laboratories. 2001. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob. Agents Chemother. 45:2775-2780.
36. Mattes, F. M., E. G. Hainsworth, A. F. Hassan-Walker, A. K. Burroughs, P. Sweny, P. D. Griffiths, and V. C. Emery. 2005. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J. Infect. Dis. 191:89-92.
37. Paya, C., A. Humar, E. Dominguez, K. Washburn, E. Blumberg, B. Alexander, R. Freeman, N. Heaton, M. D. Pescovitz, and Valganciclovir Solid Organ Transplant Study Group. 2004. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4:611-620.
38. Pelosi, E., F. Rozenberg, D. M. Coen, and K. L. Tyler. 1998. A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice. Virology 252:364-372.
39. Scott, G. M., M. A. Isaacs, F. Zeng, A. M. Kesson, and W. D. Rawlinson. 2004. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J. Med. Virol. 74:85-93.
40. Scott, G. M., H. L. Ng, C. J. Morton, M. W. Parker, and W. D. Rawlinson. 2005. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus. J. Gen. Virol. 86:2141-2151.
41. Soderberg-Naucler, C., and V. C. Emery. 2001. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 71:SS24-SS30.
42. Springer, K. L., S. Chou, S. Li, R. H. Giller, R. Quinones, J. E. Shira, and A. Weinberg. 2005. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus- infected hematopoietic cell transplant recipients. J. Clin. Microbiol. 43:208-213.
43. Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
44. Tchesnokov, E. P., C. Gilbert, G. Boivin, and M. Gotte. 2006. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. J. Virol. 80:1440-1450.
45. Wang, J., A. K. Sattar, C. C. Wang, J. D. Karam, W. H. Konigsberg, and T. A. Steitz. 1997. Crystal structure of a pol alpha family replication DNA polymerase from bacteriophage RB69. Cell 89:1087-1099.
46. Weinberg, A., D. A. Jabs, S. Chou, B. K. Martin, N. S. Lurain, M. S. Forman, and C. Crumpacker. 2003. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J. Infect. Dis. 187:777-784.
47. Ye, L. B., and E. S. Huang. 1993. In vitro expression of the human cytomegalovirus DNA polymerase gene: effects of sequence alterations on enzyme activity. J. Virol. 67:6339-6347.